Xeris Biopharma Holdings, Inc.XERS stock score: 64/100
$16.62 · -2.18% · Scored Nov 19, 2026
- Technical
- 68
- Fundamental
- 63
- News
- —
The reading
Xeris Biopharma (XERS) scores 64 out of 100, which reads neutral, higher than 87% of Healthcare stocks and 89% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 63, technicals 68.
Among the fundamentals, Earnings Growth (Annual) at 100 and Revenue Growth (5-Year) at 99 score highest, while Price to Book Ratio at 0 weighs the most against it.
On the daily chart, trend-following indicators average 75 and contrarian oscillators 22 — a split worth reading before trusting the technical total.
Since Aug 23, 2026 the composite has ranged from 56 to 66, and it ends the period where it started.
About Xeris Biopharma
Xeris Biopharma Holdings (XERS) is a biopharmaceutical company that develops and sells medicines for endocrine and other specialty conditions. Its main growth product is Recorlev, a treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome, a rare condition in which the body produces too much cortisol. Xeris also sells Gvoke, a ready-to-use liquid glucagon for severe low blood sugar in people with diabetes, offered in an autoinjector, prefilled syringe and other forms, and Keveyis, a treatment for primary periodic paralysis. The company uses its XeriSol and XeriJect formulation technologies to create stable, ready-to-use injectable versions of drugs, and it licenses these technologies to other drugmakers. Its pipeline includes a once-weekly injectable form of levothyroxine for hypothyroidism. Xeris sells its products mainly in the United States through specialty pharmacies and distributors, and it earns money mainly from product sales, with some revenue from licensing and partnerships.
Recorlev competes with Recordati’s Isturisa and Corcept Therapeutics’ Korlym, while Gvoke competes with Amphastar’s Baqsimi and generic glucagon kits. Xeris’s edge rests on its formulation technology, a specialized endocrinology sales force and its focus on rare and underserved conditions. Investors who follow XERS stock tend to watch Recorlev sales and the number of patients on therapy. Gvoke prescriptions and insurance coverage are closely followed. Progress of its weekly levothyroxine program, profitability and debt levels are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward XERS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
63Pulling it up
Net income growth from the prior fiscal year to the latest.
5-year revenue growth analyzes long-term sales trajectory and consistency.
Annual revenue growth tracks year-over-year sales expansion.
Holding it back
Price-to-Book ratio compares market value to book value.
Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholder equity.
Trailing P/E ratio uses the last 12 months of actual earnings.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
68Pulling it up
Rate of Change measures the percentage change in price over a specified period.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- VWAP100
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Holding it back
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 48 | 1 |
| Daily | 68 | 3 |
| Weekly | 72 | 2 |
| Monthly | 75 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 64 |
| Nov 18, 2026 | 64 |
| Nov 17, 2026 | 64 |
| Nov 16, 2026 | 64 |
| Nov 15, 2026 | 65 |
| Nov 14, 2026 | 65 |
| Nov 13, 2026 | 65 |
| Nov 12, 2026 | 66 |
| Nov 11, 2026 | 64 |
| Nov 10, 2026 | 63 |
| Nov 7, 2026 | 64 |
| Nov 6, 2026 | 62 |
| Nov 5, 2026 | 62 |
| Nov 4, 2026 | 60 |
| Nov 3, 2026 | 59 |
| Nov 2, 2026 | 59 |
| Nov 1, 2026 | 61 |
| Oct 30, 2026 | 61 |
| Oct 29, 2026 | 61 |
| Oct 28, 2026 | 61 |
| Oct 27, 2026 | 61 |
| Oct 26, 2026 | 59 |
| Oct 25, 2026 | 59 |
| Oct 24, 2026 | 59 |
| Oct 23, 2026 | 59 |
| Oct 22, 2026 | 61 |
| Oct 21, 2026 | 62 |
| Oct 20, 2026 | 63 |
| Oct 19, 2026 | 62 |
| Oct 18, 2026 | 61 |
| Oct 17, 2026 | 61 |
| Oct 16, 2026 | 61 |
| Oct 15, 2026 | 61 |
| Oct 14, 2026 | 60 |
| Oct 13, 2026 | 62 |
| Oct 12, 2026 | 63 |
| Oct 11, 2026 | 63 |
| Oct 10, 2026 | 63 |
| Oct 9, 2026 | 63 |
| Oct 8, 2026 | 62 |
| Oct 7, 2026 | 62 |
| Oct 6, 2026 | 63 |
| Oct 5, 2026 | 63 |
| Oct 4, 2026 | 61 |
| Oct 3, 2026 | 61 |
| Oct 2, 2026 | 61 |
| Oct 1, 2026 | 61 |
| Sep 30, 2026 | 62 |
| Sep 29, 2026 | 63 |
| Sep 28, 2026 | 63 |
| Sep 27, 2026 | 63 |
| Sep 26, 2026 | 63 |
| Sep 25, 2026 | 63 |
| Sep 24, 2026 | 63 |
| Sep 23, 2026 | 63 |
| Sep 22, 2026 | 63 |
| Sep 21, 2026 | 63 |
| Sep 20, 2026 | 60 |
| Sep 19, 2026 | 60 |
| Sep 18, 2026 | 60 |
| Sep 17, 2026 | 60 |
| Sep 16, 2026 | 58 |
| Sep 15, 2026 | 57 |
| Sep 14, 2026 | 57 |
| Sep 13, 2026 | 57 |
| Sep 12, 2026 | 57 |
| Sep 11, 2026 | 56 |
| Sep 10, 2026 | 56 |
| Sep 9, 2026 | 57 |
| Sep 8, 2026 | 62 |
| Sep 7, 2026 | 61 |
| Sep 6, 2026 | 61 |
| Sep 5, 2026 | 61 |
| Sep 4, 2026 | 62 |
| Sep 2, 2026 | 62 |
| Sep 1, 2026 | 61 |
| Aug 31, 2026 | 62 |
| Aug 30, 2026 | 62 |
| Aug 29, 2026 | 62 |
| Aug 28, 2026 | 62 |
| Aug 27, 2026 | 63 |
| Aug 26, 2026 | 64 |
| Aug 25, 2026 | 63 |
| Aug 24, 2026 | 64 |
| Aug 23, 2026 | 64 |
Key facts
- Market cap
- $3.0B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.84
- Risk grade (1–10)
- 8
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| HIMS Hims & Hers Health | $3.8B | 54 |
| AMLX Amylyx Pharmaceuticals | $3.4B | 52 |
| BHC Bausch Health Companies | $3.2B | 64 |
| PBH Prestige Consumer Healthcare | $2.4B | 59 |
| HCM HUTCHMED (China) | $2.3B | 60 |
| PRGO Perrigo Company | $2.2B | 48 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is XERS's stock rating today?
XERS scores 64/100 (Neutral) as of Nov 19, 2026: technical 68, fundamental 63. Scores are recomputed every night.
What does Xeris Biopharma do?
Xeris Biopharma Holdings (XERS) is a biopharmaceutical company that develops and sells medicines for endocrine and other specialty conditions. Its main growth product is Recorlev, a treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome, a rare condition in which the body produces too much cortisol.
Is XERS stock a buy?
The score is not a buy or sell recommendation. A 64 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the XERS score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/xers/"><img src="https://stocksscores.com/stocks/xers/badge.svg" alt="XERS stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/xers/)